mm1313亚洲精品,欧美俄罗斯40老熟妇,欧美日韩在线观看视频在线,亚洲欧美国产激情综合在线

掃碼關注公眾號           掃碼咨詢技術支持           掃碼咨詢技術服務
  
客服熱線:400-901-9800  客服QQ:4009019800  技術答疑  技術支持  質(zhì)量反饋  關于我們  聯(lián)系我們
日韩一二三四区精品电影免费播放,理论片高清免费理论片,欧美亚洲中文字幕资源
首頁 > 產(chǎn)品中心 > 一抗 > 產(chǎn)品信息
Digoxin Mouse mAb (bsm-33046M)  
訂購熱線:400-901-9800
訂購郵箱:sales@www.p2b3.cn
訂購QQ:  400-901-9800
技術支持:techsupport@www.p2b3.cn
50ul/1180.00元
100ul/1980.00元
200ul/2800.00元
200ug(PBS only)/5600.00元
大包裝/詢價

產(chǎn)品編號 bsm-33046M
英文名稱 Digoxin Mouse mAb
中文名稱 地高辛單克隆抗體
別    名 Lanoxin.  
產(chǎn)品類型 小分子抗體 
研究領域 細胞生物  免疫學  藥物及化合物  
抗體來源 Mouse
克隆類型 Monoclonal
克 隆 號 6H7
交叉反應 Human (predicted: Digoxin)
產(chǎn)品應用 ELISA=1:1000-10000
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
理論分子量 kDa
檢測分子量
性    狀 Liquid
濃    度 1mg/ml
免 疫 原 KLH conjugated Digoxin 
亞    型 IgG
純化方法 affinity purified by Protein G
緩 沖 液 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
保存條件 Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles.
注意事項 This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
PubMed PubMed
產(chǎn)品介紹 Digoxin is a beta blocker drug originally derived from the foxglove plant, Digitalis lanata. Digoxin is used primarily to improve the pumping ability of the heart in congestive heart failure (CHF), and treat problems such as high blood pressure. It is also used to help normalize some dysrhythmias (abnormal types of heartbeat).

產(chǎn)品圖片
Measured by its binding ability in a indirect ELISA. Immobilized Human Digoxin protein, His Tag (Cat. bs-33046P) at 2 μg/mL (100 μL/well) can bind ? Mouse Anti-Human Digoxin Antibody, the EC50 is 11.22 ng/mL.
版權所有 2004-2026 www.www.p2b3.cn 北京博奧森生物技術有限公司
通過國際質(zhì)量管理體系ISO 9001:2015 GB/T 19001-2016    證書編號: 00124Q34771R2M/1100
通過國際醫(yī)療器械-質(zhì)量管理體系ISO 13485:2016 GB/T 42061-2022    證書編號: CQC24QY10047R0M/1100
京ICP備05066980號-1         京公網(wǎng)安備110107000727號
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |